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SUBJECTS: 




Arabidopsis thaliana glyoxalase 2-1 (GLX2-1) exhibits extensive sequence similarity with GLX2 enzymes but is 
catalytically inactive with SLG, the GLX2 substrate. In an effort to identify residues essential for GLX2 activity, 
amino acid residues were altered at positions 219, 246, 248, 325, and 328 in GLX2-1 to be the same as those in 
catalytically active human GLX2. The resulting enzymes were overexpressed, purified, and characterized using 
metal analyses, fluorescence spectroscopy, and steady-state kinetics to evaluate how these residues affect 
metal binding, structure, and catalysis. The R246H/N248Y double mutant exhibited low level S-
lactoylglutathione hydrolase activity, while the R246H/N248Y/Q325R/R328K mutant exhibited a 1.5−2-fold 
increase in kcat and a decrease in Km as compared to the values exhibited by the double mutant. In contrast, the 
R246H mutant of GLX2-1 did not exhibit glyoxalase 2 activity. Zn(II)-loaded R246H GLX2-1 enzyme bound 2 equiv 
of Zn(II), and 1H NMR spectra of the Co(II)-substituted analogue of this enzyme strongly suggest that the 
introduced histidine binds to Co(II). EPR studies indicate the presence of significant amounts a dinuclear metal 
ion-containing center. Therefore, an active GLX2 enzyme requires both the presence of a properly positioned 
metal center and significant nonmetal, enzyme−substrate contacts, with tyrosine 255 being particularly 
important. 
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The glyoxalase system consists of two enzymes, lactoylglutathione lyase (GLX1) and hydroxyacylglutathione 
hydrolase (GLX2). GLX1 is capable of forming S-(2-hydroxyacyl)glutathione (SLG),1 which is produced from a 
thiohemiacetal that is formed from the spontaneous reaction of methylglyoxal with glutathione. SLG is then 
hydrolyzed by GLX2 to produce lactate and glutathione. GLX1 can utilize a number of α-ketoaldehydes; however, 
methylglyoxal (MG), a cytotoxic and mutagenic compound formed primarily as a byproduct of carbohydrate and 
lipid metabolism and from triose phosphates, is thought to be the primary physiological substrate of the 
system(1-5). SLG can also be metabolized by γ-glutamyltransferase and dipeptidase, which generate N-d-
lactoylcysteine that passes from cell to cell and can inhibit nucleotide synthesis(6) and ultimately DNA 
synthesis (7). Therefore, the glyoxalase system, which depletes MG and SLG, is critical for cellular detoxification 
in aerobic organisms (6). 
Abbreviations: EDTA, ethylenediaminetetraacetic acid; ICP-AES, inductively coupled plasma with atomic 
emission spectroscopy; LB, Luria−Bertani; MOPS, 3-(N-morpholino)propanesulfonic acid; SLG, S-d-
lactoylglutathione. 
 
GLX1 from a number of sources has been studied extensively using biochemical, computational, and X-ray 
crystallographic approaches (8). In contrast, GLX2 has been considerably less well characterized. In humans, a 
single gene encodes the mitochondrial and cytoplasmic forms of GLX2 (9). On the other hand, Arabidopsis 
thaliana contains four putative GLX2 genes, including multiple mitochondrially localized forms of GLX2 (GLX2-1, 
GLX2-4, and GLX2-5), as well as a gene for a cytosolic enzyme (GLX2-2) (10). The presence of multiple putative 
mitochondrial GLX2 enzymes is surprising because GLX1 and SLG have only been observed in the cytosol of 
cells (11, 12). Subsequent studies confirmed that GLX2-2 and GLX2-5 are in fact GLX2 isozymes and that they 
contain dinuclear metal binding sites (1, 13, 14). 
The crystal structures of human cytoplasmic and plant mitochondrial GLX2 (GLX2-5) (Figure 1) showed that the 
metal binding and active sites of GLX2 are most similar to that of metallo-β-lactamase L1 
from Stenotrophomonas maltophilia(1, 15, 16). One of the metal binding sites (Zn1 site) consists of three 
conserved histidine residues, a bridging aspartic acid, and a bridging water/hydroxide. The second metal-binding 
site (Zn2 site) has two histidines, one bridging Asp, a nonbridging Asp, a terminally bound water, and the bridging 
hydroxide/water. It was initially hypothesized that human GLX2 contains a dinuclear Zn(II)-containing center; 
however, recent studies have shown that human GLX2 contains a FeZn center, similar to that reported 
for Arabidopsis GLX2-5 (17). 
 
Figure 1. Crystal structure of A. thaliana GLX2-5 and human GLX2 (1, 15). Numbering scheme corresponds to the 
sequences in Figure 2. 
 
GLX2-1 is unique among GLX2-like enzymes in that it has an Arg instead of a metal binding His at position 246 
(Figure 2)(1, 15). Although GLX2-1 and GLX2-5 share ∼80% amino acid sequence identity and ∼88% amino acid 
sequence similarity, we recently showed that recombinant GLX2-1 does not hydrolyze SLG or a number of other 
GLX2 substrates (18). Therefore, GLX2-1 is not a GLX2 isozyme. Our studies did however show that GLX2-1 
exhibits β-lactamase activity and still binds 2 equiv of metal. 
 
Figure 2. Alignment of predicted plant glyoxalase II's from A. thaliana. The * marks the metallo-β-lactamase fold 
motif. The # marks the highly conserved metal binding residues. The Δ marks the substrate binding residues. 
 
The crystal structure of human GLX2 complexed with a slowly processed substrate revealed that eight active site 
amino acids make considerable contacts with the substrate. Five of these amino acids (Lys217, Tyr219, Tyr248, 
Arg325, and Lys328) (19, 20), which are conserved in GLX2-5 and in other GLX2's, are absent in GLX2-1. We were 
therefore interested in determining which of these amino acids are most important for GLX2 activity and 
predicted that we could introduce GLX2 activity into GLX2-1 by generating site-directed mutants of GLX2-1 
containing the substrate/metal binding amino acids that are present in human GLX2. Enzymes containing single 
and multiple amino acid substitutions were generated, and the resulting mutants were overexpressed, purified, 
and characterized using metal analyses, fluorescence spectroscopy, and steady-state kinetics to evaluate how 
these residues affect metal binding, structure, and catalysis. Our data show that two amino acid substitutions, 
R246H and N248Y, were enough to generate S-lactoylglutathione hydrolase activity. 
Experimental Procedures 
Homology Modeling 
Molecular modeling of GLX2-1 was carried out using the SWISS-MODEL program (http://swissmodel.expasy.org) 
in conjunction with the Swiss PdbViewer, DeepView (http://www.expasy.org/spdbv/). A homology model of 
GLX2-1 was constructed using the NCBI sequences (http://www.ncbi.nlm.nih.gov) and modeling against the PDB 
structures 1XM8 (A. thaliana GLX2 gene AT2G31350), 1QH5 (human GLX2 with S-(N-hydroxy-N-
bromophenylcarbamoyl)glutathione), and 2Q42 (ensemble refinement of the protein crystal structure of A. 
thaliana GLX2 gene At2g31350). Model generation was performed in Project mode using the sequence 
alignment seen in Figure 2. The project file was submitted to the server, and the resulting structure was 
evaluated using ProSA-web (Z-score 1.04). The metal center's coordinates were duplicated from 1XM8 and 
measured for ligand−metal distance consistency between the model and template structures. The resulting 
structure was utilized without further refinement. Distance measurements and rotamer confirmations were 
calculated, and images were generated using UCSF Chimera (http://www.cgl.ucsf.edu/chimera). 
Generation of GLX2-1 Active Site Mutations and the H238R Mutant of GLX2-5 
The N-terminus of overexpressed GLX2-1 was chosen to be identical to that for A. thaliana GLX2-5(1, 18). The 
QuikChange site-directed mutagenesis kit was used to make the R246H, R246H/N248Y, 
R246H/N248Y/Q325R/R328K, and R246H/N248Y/Q325R/R328K/S219F mutants of GLX2-1 and the H238R 
mutant of GLX2-5. PCR was conducted on either GLX2-1/pT7-7 or GLX2-5/pT7-7 with the primers shown in 
Table 1 to generate the mutants. DNA sequencing using the T7 promoter and T7 terminator primers was used to 
confirm the resulting mutations. The resulting plasmids were transformed into Escherichia coli BL21(DE3) cells 
for overexpression studies. The coexpression plasmid, pGroESL, was transformed into BL21(DE3) E. coli cells 
containing H238RGLX2-5/pT7-7 to assist in proper protein folding. 
Table 1. Oligonucleotide Primers for Site-Directed Mutagenesis 
code comment 5′−3′ nucleotide sequence 
1021 R246H GLX2-1 forward CAA ATA TAT ACT GCG GCC ATG AAA ACA CAG CAG GC 
1022 R246H GLX2-1 reverse GCC TGC TGT GTT TTC ATG GCC GCA GTA TAT ATT TG 
1023 R246H/N248Y GLX2-1 forward CAA ATA TAT ACT GCG GCC ATG AAT ACA CAG CAG GCA 
ATC TCA AG 
1024 R246H/N248Y GLX2-1 reverse CTT GAG ATT GCC TGC TGT GTA TTC ATG GCC GCA GTA 
TAT ATT TG 
1025 R246H/N248Y/Q325R/R328K GLX2-1 
forward 
GAA GCA TTG CGT CGT ATA CGG AGA GCC AAA GAT CGT 
TTC 
1026 R246H/N248Y/Q325R/R328K GLX2-1 
reverse 




CAA TAT TCA CAG GAG ACC TGA TAT TTA GCT TAT CCT 
GTG GTA C 
1028 R246H/N248Y/Q325R/R328K/S219F 
GLX2-1 reverse 
GTA CCA CAG GAT AAG CTA AAT ATC AGG TCT CCT GTG 
AAT ATT G 
1029 H238R GLX2-5 forward CAC AAG CAT ATA CTG TGG TCG TGA ATA TAC ACT GAG 
TAA TTC C 
1030 H238R GLX2-5 reverse GGA ATT ACT CAG TGT ATA TTC ACG ACC ACA GTA TAT 
GCT TGT G 
 
Overexpression and Purification of GLX2-1 and GLX2-5 Mutant Enzymes 
A 10 mL overnight culture of BL21(DE3) E. coli containing the R246H, R246H/N248Y, 
R246H/N248Y/G325R/G328K, and R246H/N248Y/G325R/G328K/S219F forms of pGLX2-1/pT7-7 was used to 
inoculate 1 L of LB (Luria−Bertani) medium containing ampicillin (150 μg/mL), 250 μM Fe(NH4)2(SO4)2, and 250 
μM Zn(SO4)2. The cells were grown, induced for protein overexpression, and harvested as previously 
described (18). For overexpression of the GLX2-5 H238R mutant, the pGroESL plasmid was transformed into 
the E. coli BL21(DE3) cells containing the H238RGLX2-5/pT7-7 plasmid and overexpressed as described above. 
Purification of all mutants was accomplished using previously published procedures (18). Protein purity was 
ascertained by using sodium dodecyl sulfate−polyacrylamide gel electrophoresis (SDS−PAGE). Enzyme-
containing fractions (8 mL) were pooled and concentrated by using an Amicon ultrafiltration cell equipped with 
a YM-10 membrane. Enzyme concentrations were determined by measuring the absorbance at 280 nm and 
using a molar extinction coefficient of 25400 M−1 cm−1(18). 
Metal Analyses 
The metal content of the enzymes was determined using an ICAP 61E trace analyzer (TJA; Thermo Jarrell Ash 
Corp.) with atomic emission spectroscopy detection (ICP-AES) as described previously (21). Protein samples 
were diluted to 10 μM with 10 mM MOPS, pH 7.2. 
To evaluate metal binding to wild-type GLX2-1 and the mutant forms of the enzyme, a 3-fold molar excess of 
Zn(SO4)2 or Fe(NH4)2(SO4)2 or 1.5-fold molar excess of both Fe(NH4)2(SO4)2 and Zn(SO4)2 was added directly to the 
as-isolated enzymes, and the mixtures were allowed to incubate on ice for 1 h. Unbound or loosely bound metal 
ions were removed by 6 × 1 L dialysis steps against 10 mM MOPS, pH 7.2, at 4 °C (12 h for each step). The metal 
content of these samples was determined using ICP-AES as described above. 
Preparation of Co(II)-Substituted GLX2-1 R246H 
The metal-free (apo) R246H version of GLX2-1 was prepared by dialyzing a 0.1 mM solution of the protein 
against 4 × 2 L of 10 mM 1,10-phenanthroline in 10 mM MOPS, pH 6.5, at 4 °C, followed by dialysis versus 6 × 1 L 
of Chelex-treated, 10 mM MOPS, pH 6.5, at 4 °C. ICP-AES was used to confirm that the sample was metal-free. 
CoCl2 was added directly to the sample to generate the Co(II)-substituted protein. 
NMR Studies 
1H NMR spectra were collected on a Bruker Avance 500 spectrometer operating at 500.13 MHz, 298 K, magnetic 
field of 11.7 T, recycle delay (AQ) of 41 ms, and sweep width of 400 ppm. Chemical shifts were referenced by 
assigning the H2O signal the value of 4.70 ppm. A modified presaturation pulse sequence (zgpr) was used to 
suppress the proton signals originating from solvent and amino acids not coupled to the metal center. The 
concentration of protein was ∼1 mM, and 10% D2O was included in samples for locking. 
Steady-State Kinetics 
The steady-state kinetic parameters (Km, kcat) of the wild-type GLX2-1, GLX2-5, and the GLX2 variants were 
determined using S-d-lactoylglutathione (SLG) as the substrate. SLG hydrolysis was monitored at 240 nm over 30 
s at 25 °C as previously reported (21). The concentration of GLX2 in the samples was typically 1−10 nM, and 
substrate concentrations ranged between 30 and 600 μM. The buffer used in the steady-state kinetic studies 
was 10 mM MOPS, pH 7.2. 
Fluorescence Spectra of the GLX2-1 Variants 
A Perkin-Elmer LS55 luminescence spectrometer, tuned to an excitation wavelength of 295 nm and emission 
wavelength of 340 nm with a slit width of 5 nm, was used to monitor fluorescence emission intensities of the 
mutants. A 4 mm quartz cuvette was used, and the protein concentrations were 10 μM. Chelex-treated 10 mM 
MOPS, pH 7.2, was used as a buffer blank. 
EPR Studies of GLX2-5 H238R 
EPR spectra were recorded using a Bruker E600 EleXsys spectrometer equipped with an Oxford Instruments 
ESR900 helium flow cryostat and ITC503 temperature controller and an ER4116DM cavity operating at 9.63 GHz 
in perpendicular mode. Other recording parameters are given in the legend to Figure 6. Quantitation of signals 
was carried out by double integration of spectra recorded at nonsaturating power (2 mW) at 12 K. A 2 mM 
Cu(II)-EDTA standard in HEPES, pH 7.5, recorded at 60 K, 50 μW, was used. Integration limits and correction 
factors for S = 1/2 and S = 5/2 signals, where D is assumed to be small compared to temperature, were used as 
employed elsewhere (22) and recently described explicitly by Bou-Abdallah and Chasteen and references 
therein (23, 24). Computer simulations of EPR spectra were carried out using XSophe (25). 
Results 
Homology Modeling 
We previously showed that GLX2-1 contains a dinuclear metal center even though the enzyme contains an Arg 
in place of a His in the conserved β-lactamase metal binding ligands (18). This raised the question of whether the 
GLX2-1 structure is significantly different from a typical GLX2 enzyme or if subtle structural alterations might 
position a more typical metal binding ligand near the metal center. We have attempted to crystallize the enzyme 
and perform a structural analysis to answer this question. Unfortunately, these studies have been unsuccessful 
to date; therefore, modeling studies were undertaken to investigate these questions. Modeling of GLX2-1 
against human GLX2 and A. thaliana GLX2-5 rendered a virtually identical tertiary structure for GLX2-1 as 
compared to the other two enzymes (Figure 3). This is not surprising given the high sequence conservation 
between the enzymes (human, 35% identity, 53% similarity; GLX2-5, 74% identity, 85% similarity). However, the 
model unexpectedly predicted that Arg246, which is a metal binding His in GLX2-2, GLX2-5, and human GLX2, is 
positioned directly over the Zn2 metal binding site and is within binding distance of the metal ion in that site. The 
modeling prediction that Arg246 could bind a metal ion in the Zn2 site is in contrast to our recent results that 
show that the R246L mutant of GLX2-1 binds 2 equiv of metal. Nonetheless, the predicted position of Arg246 in 
the GLX2-1 model suggests that this residue restricts access of the substrate to the Zn2 metal binding site. The 
model does not show any other potential metal binding ligands in the vicinity of the Zn(II), suggesting that the 
positive charge on Arg246 must be neutralized if it coordinates a metal ion. 
 
Figure 3. Computational model of the active site of GLX2-1 overlapped with the active site of GLX2-5. Metal 
binding ligands are the same in both models except residue Arg246. Gray residues indicate the metal binding 
sites of GLX2-1, and black residues indicate the metal binding site of GLX2-5. 
 
The computer model of GLX2-1 also predicted that many of the key residues utilized for substrate binding in 
human GLX2 are different in GLX2-1 (Figure 3). Most notably, GLX2-1 has an asparagine at position 248, whereas 
human GLX2 contains a tyrosine that hydrogen bonds to the thioether of the substrate (15). In addition, human 
GLX2 contains an Arg at position 326 that hydrogen bonds to the carboxyl terminus of the substrate, while the 
model of GLX2-1 shows the presence of a glutamine at the same position. The GLX2-1 model did not reveal 
other residues in close proximity to the putative substrate binding site that could accommodate the loss of these 
substrate binding residues. Therefore, we hypothesized that the lack of catalytic activity exhibited by GLX2-
1 (18) is due to the inability of the protein to bind SLG. To test this hypothesis, site-directed mutants of GLX2-1 
were generated and characterized. 
Overexpression and Purification of GLX2-1 Variants 
The R246H, N248Y, R246H/N248Y, R246H/N248Y/Q325R/R328K, and R246H/N248Y/Q325R/R328K/S219F 
mutants were generated using site-directed mutagenesis, and the resulting mutations were confirmed by DNA 
sequencing. Since Gln325 and Arg328 are so close in the protein sequence, we used a single primer to generate 
the R246H/N248Y/Q325R/R328K mutant, rather than preparing triple mutants. The mutant enzymes were 
overexpressed and purified as soluble proteins. Approximately 25−30 mg of colorless protein was obtained from 
1 L of culture for wild-type GLX2-1 and each of the GLX2-1 mutant enzymes. 
Metal Analyses 
To determine if the mutations affected metal binding, the metal content of the purified GLX2-1 mutant enzymes 
was measured using ICP-AES. When wild-type GLX2-1 is overexpressed in LB medium containing 250 μM 
Fe(NH4)2(SO4)2 and 250 μM Zn(SO4)2, enzyme containing equal, albeit less than stoichiometric, amounts of Fe 
and Zn(II) was obtained (18) (Table 2). In contrast, the GLX2-1 R246H enzyme contained nearly 2 equiv of Zn(II) 
and undetectable amounts of Fe. The purified N248Y mutant contained very little metal, and its fluorescence 
spectrum suggested significant amounts of unfolded protein (data not shown). All of the other mutants that 
contained the R246H mutation were isolated containing various amounts of Zn(II) and little or no Fe (Table 2). 
Table 2. Metal Content and Steady-State Kinetic Constants for Wild-Type and Mutant GLX2-1 and GLX2-5 
Analogues 
protein kcat (s−1) Km (μM) kcat/Km (μM−1 s−1) Fe (equiv) Zn (equiv) 
wild-type GLX2-1           
as-isolated N/Aa N/A N/A 0.3 ± 0.1b 0.3 ± 0.2b 
Zn(II) addedc N/A N/A N/A ∼0.1b 1.6 ± 0.2b 
Fe(II) addedd N/A N/A N/A 1.9 ± 0.1b 0.2 ± 0.1b 
Fe(II) and Zn(II) addede N/A N/A N/A 1.6 ± 0.2b 1.6 ± 0.2b 
R246H GLX2-1           
as-isolated N/A N/A N/A NDf 1.7 ± 0.3 
Zn(II) addedc N/A N/A N/A ND 2.0 ± 0.2 
Fe(II) addedd N/A N/A N/A 3.3 ± 0.3 1.2 ± 0.2 
Fe(II) and Zn(II) addede N/A N/A N/A 0.8 ± 0.3 1.7 ± 0.3 
R246H/N248Y GLX2-1           
as-isolated 2.1 ± 0.2 295 ± 40 0.007 ± 0.005 0.2 ± 0.1 1.2 ± 0.2 
Zn(II) addedc 23 ± 4 310 ± 110 0.07 ± 0.04 ND 2.4 ± 0.1 
Fe(II) addedd 19 ± 2 257 ± 58 0.07 ± 0.03 3.5 ± 0.3 1.2 ± 0.3 
Fe(II) and Zn(II) addede 22 ± 2 370 ± 60 0.06 ± 0.03 0.6 ± 0.2 2.5 ± 0.1 
R246H/N248Y/Q325R/R328K GLX2-1           
as-isolated 17 ± 2 249 ± 31 0.07 ± 0.05 ND 1.2 ± 0.2 
Zn(II) addedc 30 ± 2 238 ± 41 0.12 ± 0.05 ND 1.5 ± 0.1 
Fe(II) addedd 22 ± 2 290 ± 59 0.07 ± 0.04 1.9 ± 0.2 1.2 ± 0.3 
Fe(II) and Zn(II) addede 38 ± 5 285 ± 78 0.13 ± 0.06 1.1 ± 0.1 1.5 ± 0.1 
R246H/N248Y/Q325R/R328K/S219F 
GLX2-1 
          
as-isolated 16 ± 1 240 ± 39 0.07 ± 0.03 ND 1.1 ± 0.3 
Zn(II) addedc 17 ± 2 186 ± 55 0.09 ± 0.04 ND 1.4 ± 0.1 
Fe(II) addedd 20 ± 3 313 ± 55 0.06 ± 0.03 3.4 ± 0.3 0.5 ± 0.2 
Fe(II) and Zn(II) addede 20 ± 3 220 ± 72 0.09 ± 0.03 1.1 ± 0.1 1.4 ± 0.1 
GLX2-5           
as-isolated wild-type 180 ± 20 267 ± 63 0.67 ± 0.31 0.6 ± 0.1 1.8 ± 0.1 
as-isolated H238R 0.32 ± 0.04 303 ± 79 0.001 ± 0.001 0.7 ± 0.2 0.6 ± 0.2 
Fe(II) and Zn(II) addede 31 ± 2 194 ± 32 0.16 ± 0.7 1.1 ± 0.1 1.7 ± 0.1 
aN/A: no activity. 
bPreviously published results (18). 
c3-fold excess of Zn(II) added after purification. 
d3-fold excess of Fe(II) added after purification. 
e1.5-fold excess of Fe plus 1.5-fold excess of Zn(II) added after purification. 
fND: none detected. 
 
We further investigated the ability of the GLX2-1 variants to bind metal by the addition of metal to the purified 
proteins followed by extensive dialysis to remove loosely bound or unbound metal. The addition of a 3-fold 
molar excess of ZnSO4 or Fe(NH4)2(SO4)2 to wild-type GLX2-1 resulted in analogues that bind nearly 2 equiv of 
the metal that was added. The addition of a 1.5-fold molar excess of both Fe(NH4)2(SO4)2 and ZnSO4 to wild-type 
GLX2-1 resulted in an analogue that binds equal amounts of Fe and Zn(II), with a total metal content greater 
than 3 equiv, suggesting some nonspecific binding of metal. 
The addition of a 3-fold molar excess of ZnSO4 to the GLX2-1 mutant enzymes resulted in analogues that bound 
only Zn(II) at levels ranging from 1.4 to 2.4 equiv (Table 2). The addition of a 3-fold molar excess of 
Fe(NH4)2(SO4)2 to the GLX2-1 mutant enzymes resulted in analogues that bound up to 4 equiv of Fe yet retained 
significant amounts of Zn(II) binding. This result suggests that His246 in the GLX2-1 metal binding site confers a 
preference for Zn(II) to at least one site, even in the presence of excess Fe. In addition, this result suggests that 
the R246H mutation generates additional Fe binding sites since all of the GLX2-1 mutant enzymes containing the 
R246H mutation can bind up to 4 equiv of total metal. 
NMR Spectroscopy on GLX2-1 R246H 
To identify the metal binding ligands in the R246H GLX2-1 enzyme, 1H NMR spectra were obtained on the Co(II)-
substituted protein (2Co-R246H GLX2-1). The 1H NMR spectrum of 2Co-R246H GLX2-1 in 10% D2O revealed six 
paramagnetically shifted resonances between 20 and 80 ppm (Figure 4). The peak at 63 ppm integrated to two 
protons, while the peaks at 49, 44, 28, and 21 ppm integrated to one proton each, and the peak at 31 ppm 
integrated to slightly less than one proton. The spectrum of the same enzyme in 90% D2O showed that the peaks 
at 63, 49, and 44 ppm disappear and that the peak at 28 ppm is reduced in intensity by one-half. These solvent-
exchangeable resonances can be readily assigned to N−H protons on Co(II)-bound histidines. This result indicates 
that there are five histidines bound to Co(II) in 2Co-R246H GLX2-1 and strongly suggests that the introduced His 
at position 253 binds metal. 
 
Figure 4. 1H NMR spectrum of the 2Co-R246H mutant of GLX2-1 in 10 mM MOPS, pH 7.2, containing 10% D2O. 
The enzyme concentration in the samples was ∼1 mM. The * represents peaks that were solvent-exchangeable. 
Peak e in the spectrum decreased by one-half when the sample was exchanged in 90% D2O. 
 
Steady-State Kinetics 
Steady-state kinetic studies using SLG as the substrate were performed on the as-isolated GLX2-1 mutant 
enzymes to determine if any of the mutations resulted in an active enzyme. The R246H mutant, which was 
generated to yield a GLX2-1 variant with the same metal binding ligands as human GLX2 and GLX2-5, did not 
hydrolyze SLG (Table 2). On the other hand, the R246H/N248Y enzyme was active toward SLG and exhibited 
a kcat of 2.1 ± 0.2 s−1 and a Km of 295 ± 40 μM. The kcat value for this enzyme is 86-fold lower than that of wild-
type GLX2-5 (Table 2). Introduction of the Q325R/R328K mutations into the R246H/N248Y enzyme to yield the 
R246H/N248Y/Q325R/R328K mutant resulted in an enzyme that exhibited a kcat value of 17 ± 2 s−1 and 
a Km value of 249 ± 31 μM. The kcat value of this enzyme is roughly 10-fold lower than that of GLX2-5 (Table 2). 
The introduction of a fifth mutation (S219F) to the R246H/N248Y/Q325R/R328K enzyme did not appreciably 
change the kinetic properties of the enzyme (Table 2). 
To further evaluate the catalytic activity of the GLX2-1 variants, the metal-loaded enzymes were used in steady-
state kinetic studies. The R246H form of GLX2-1 was not active independent of whether it had been incubated 
with Zn(II), Fe, or Zn/Fe (Table 2). In contrast, the R246H/N248Y variant of GLX2-1 exhibited a 10-fold increase 
in kcat, as compared to that of the as-isolated enzyme, when the enzyme contained ≥2 equiv of total metal. The 
metal-loaded R246H/N248Y/Q325R/R328K variant of GLX2-1 exhibited slightly higher kcat values than that of the 
as-isolated enzyme, and metal-loaded R246H/N248Y/Q325R/R328K/S219F GLX2-1 exhibited an even smaller 
change in kcat as compared to that of the as-isolated enzyme. The Km values exhibited by the enzymes were not 
largely affected by the amount or the identity of the metal ions bound to the catalytically active analogues 
(Table 2). 
Fluorescence Spectra of GLX2-1 Variants 
Fluorescence spectra were obtained to ascertain whether the point mutations caused changes in the tertiary 
structure of the various forms of GLX2-1 (20) (Figure 5). The GLX2-1 R246H enzyme exhibited a fluorescence 
emission spectrum similar to that of the wild-type enzyme, suggesting that the substitution did not result in a 
large change in the environment around the tryptophans of the enzyme. The fluorescence emission spectrum of 
the R246H/N248Y variant was slightly higher than that of wild-type GLX2-1, which is expected if the additional 
Tyr at position 248 contributes to the overall fluorescence of the enzyme. In contrast, the 
R246H/N248Y/Q325R/R328K and R246H/N248Y/Q325R/R328K/S219F variants exhibited significantly increased 
fluorescence emission intensities, as compared to wild-type GLX2-1. This result suggests that the intrinsic 
fluorescence of one or more of the tryptophans in wild-type GLX2-1 is quenched, and the substitutions cause a 
change in structure that alleviates this quenching. The fact that the enzymes are catalytically active and bind 
metal ions argues against the substitutions causing an unfolding of the protein. 
 
Figure 5. Fluorescence emission spectra of wild-type GLX2-1 and GLX2-1 mutants. The concentration of samples 
was 10 μM, and the buffer was 10 mM MOPS, pH 7.2. An excitation wavelength of 295 nm was used. 
 
Overexpression, Purification, and Characterization of Arabidopsis GLX2-5 H238R 
Marasinghe et al. showed that mitochondrial Arabidopsis GLX2-5 exhibits glyoxalase 2 activity, and the 
recombinant enzyme was shown to bind 2 equiv of metals per enzyme (1). The crystal structure of GLX2-5 
showed that His238 is a metal binding ligand (1). Our recent studies showed that GLX2-1, which contains an Arg 
at position 246, binds two metal ions (18). Therefore, we reasoned that another as yet unidentified amino acid is 
recruited as a metal binding ligand in the Zn2 binding site. However, the computational model of GLX2-1 
predicted that the guanidinium amine of this arginine is positioned within 2.3 Å of the Zn2 metal site, which is 
well within bonding distance (Figure 3). Furthermore, the R246H variant of GLX2-1 exhibited vastly differing 
metal binding properties as compared to wild-type GLX2-1, suggesting that Arg246 affects metal binding. 
Therefore, to probe potential roles Arg could play in metal binding or catalysis, we mutated His238 in GLX2-5 to 
an Arg and evaluated the catalytic and metal binding properties of the resulting enzyme. 
When the GLX2-5 H238R enzyme was overexpressed using standard overexpression conditions (1, 18), the 
resulting enzyme was insoluble. Therefore, the coexpression plasmid, pGroESL, was introduced into the 
overexpression cell line to assist in proper protein folding. When overexpression of GLX2-5 H238R was 
performed in the presence of 250 μM Fe(NH4)2(SO4)2 and 250 μM Zn(SO4)2 using the pGroESL-containing system, 
we obtained approximately 20−25 mg of soluble, purple protein/L of culture. This result suggests that His238 is 
important for the proper folding of GLX2-5, possibly by binding to the metal ion as the protein folds. 
The GLX2-5 variant was found to bind 0.7 ± 0.2 equiv of Fe and 0.6 ± 0.2 equiv of Zn(II) and to exhibit a kcat value 
of 0.32 ± 0.04 s−1 and a Km value of 303 ± 79 μM when SLG was used as substrate (Table 2). The H238R mutation 
makes the enzyme approximately 600-fold less active than the wild-type GLX2-5 (Table 2). When as-isolated 
GLX2-5 H238R was incubated with a 1.5-fold molar excess of Fe(NH4)2(SO4)2 and Zn(SO4)2 and the mixture was 
exhaustively dialyzed versus Chelex-treated buffer, the resulting protein was shown to bind 1.1 ± 0.1 equiv of Fe 
and 1.7 ± 0.1 equiv of Zn(II). The metal-loaded enzyme exhibited a 100-fold increase in kcat, as compared to the 
as-isolated GLX2-5 H238R enzyme, and a nearly 2-fold drop in Km (Table 2). Nonetheless, the metal-loaded GLX2-
5 H238R variant was still 6-fold less active than wild-type GLX2-5. 
The fluorescence spectra of the H238R variant of GLX2-5 showed a much higher emission intensity than the 
wild-type GLX2-5 enzyme, suggesting a significant change in the environment of Trp166 (the only Trp in GLX2-5) 
or multiple Tyr’s as a result of the substitution (Figure 7). This change in environment would have to occur over a 
large distance as Trp166 is over 20 Å away from His238. This change in tertiary structure may explain the 
lower kcat values of the mutant. 
We initially hypothesized that the presence of an arginine at position 238 of GLX2-5 would disrupt the binuclear 
metal binding center in the enzyme. However, given that the H238R variant of GLX2-5 can still bind 2 equiv of 
metal, we interrogated metal binding to this enzyme using EPR spectroscopy (Figure 6). Three types of signals 
were exhibited by the enzyme. The predominant signal from the as-isolated enzyme was a geff ∼ 4.3 signal at 
1605 G, due to MS = ±3/2 of S = 5/2 Fe(III) (Figure 6B). Associated low-field features due to the ground state MS = 
±1/2 were observed on the low-field side of the geff ∼ 4.3 resonance, ending abruptly at geff ∼ 10 (680 G). The 
signal is typical for low-symmetry Fe(III) and does not confirm whether the iron associated with it is bound in a 
specific site in the mutant. A second signal observed in the spectrum was an apparently axial signal, though a 
preliminary simulation (not shown) suggested rhombic geff values of geff ∼ 1.945, 1.845, and 1.775. This signal 
was identical to a signal from GLX2-1 (Figure 6A) and is indicative of a mixed-valence Fe(II)−Fe(III) center. The 
signal was reasonably well-simulated (Figure 6C) by explicitly assuming spin-coupled S = 5/2 and S = 2 iron ions, 
with the ions 3.5 Å apart and experiencing an exchange coupling of 18 cm−1 (detailed parameters are given in 
the caption to Figure 6). While these values do not provide a unique solution, they nevertheless support the 
assignment. A third signal was observed that is common in the spectrum of as-isolated GLX2-1 (Figure 6A) and 
the metal-loaded H238R variant of GLX2-5 (Figure 6D), but not in the as-isolated H238R variant. The signal was 
best observed by subtraction of the spectrum of the as-isolated H238R variant of GLX2-5 from that of the 
enzyme after incubation with Fe and Zn(II) (Figure 6F). A computer simulation (Figure 6E) suggested a single 
Fe(III) ion with S = 5/2 and a less than completely rhombic zero field splitting, with E/D = 0.2. The discrete value 
for E/D, and the resolution of the three gedf resonances of the MS = 3/2 doublet, suggests a small distribution in 
zero field splitting parameters (low “strains” in E) and, in turn, Fe(III) with a well-defined coordination such as 
would be expected for binding in the active site of an enzyme. 
 
Figure 6. EPR spectra from GLX2-1 and the H238R mutant of GLX2-5. (A) As-isolated wild-type GLX2-1. (B) As-
isolated H238R mutant of GLX2-5. (C) Simulation of the geff = 1.775−1.945 signal, assuming interacting Fe(III) 
(S = 5/2, isotropic g = 2.0, D = 2 cm−1, E/D = 1/3) and Fe(II) (S = 2, g = 1.92, 2.01, and 2.01, D = 15 cm−1, E/D = 
0.085), with JFe(II)−Fe(III) = 18 cm−1 and an interiron distance rFe(II)−Fe(III) = 3.5 Å. The discrepancy in line shape at the 
high-field side of the middle resonance is likely due to broadening in the experimental spectrum due to strains 
in D and/or J. (D) H238R mutant of GLX2-5 after addition of 1.5 equiv of Fe(II) and 1.5 equiv of Zn(II). (E) 
Computed spectrum, assuming S = 5/2 (Fe(III)), g = 2, D = 1 cm−1, E/D = 0.2. (F) Difference spectrum generated by 
subtraction of (B) from (D). Experimental spectra were recorded at 2 mW microwave power, 10 K, and 12 G (1.2 
mT) magnetic field modulation at 100 kHz. 
 
Discussion 
The metallo-β-lactamase fold consists of an αβ/βα sandwich motif, made up of a core unit of two β-sheets 
surrounded by solvent-exposed helices (26). Members of this superfamily contain a conserved HXHXD motif that 
has been shown to bind Zn(II), Fe, and Mn (14, 27, 28). There are several enzymes in the metallo-β-lactamase 
fold superfamily, including metallo-β-lactamases, glyoxalase 2, lactonase, rubredoxin:oxygen oxidoreductase 
(ROO), arylsulfatase, phosphodiesterase, and tRNA maturase (29). Most members of the metallo-β-lactamase 
superfamily (metallo-β-lactamases, tRNA maturase, phosphodiesterase, arylsulfatase, and lactonase) appear to 
contain dinuclear Zn(II) centers. On the other hand, rubredoxin:oxygen oxidoreductase (ROO) appears to contain 
a dinuclear iron center (30). Human GLX2 was reported to contain a dinuclear Zn(II) center (15); however, NMR 
and EPR studies recently showed that recombinant human GLX2 contains a Fe(II)Zn(II) center but that the 
catalytic activity is due to Zn(II) in the Zn1 site (17). Plant mitochondrial GLX2 (GLX2-5) has been reported to 
contain a FeZn center (1), and plant cytoplasmic GLX2 can exist with a number of possible metal centers, 
including dinuclear Fe, FeZn, and presumably dinuclear Zn(II) centers (14, 27). GloB, the GLX2 from Salmonella 
typhimurium, also is isolated containing mixtures of metal centers(31). 
Arabidopsis GLX2-1 is highly similar to GLX2-5 and is clearly a member of the metallo-β-lactamase fold 
superfamily (26). However, GLX2-1 is unique in that it contains an Arg at position 246, which is a metal binding 
His in all other GLX2 enzymes (29). Metal analyses, kinetic, and spectroscopic results demonstrated that GLX2-1 
contains a dinuclear metal center; however, it does not exhibit glyoxalase 2 activity (18). In addition to the 
histidine to arginine substitution at position 246, five of the eight amino acids present at the active site of 
human GLX2 (Lys217, Tyr219, Tyr248, Arg325, and Lys328) (Figure 2), which are involved with substrate binding 
and are conserved in GLX2-2, GLX2-4, and GLX2-5 (18-20), are not conserved in GLX2-1. We predicted that one 
or more of these changes are responsible for the inability of GLX2-1 to bind and hydrolyze SLG. In an effort to 
test this hypothesis, we generated mutants of GLX2-1 that contained a His at position 246 and that contain some 
or all of the predicted GLX2-5 substrate binding ligands (Figure 3). 
The Zn(II)-loaded R246H mutant of GLX2-1 tightly bound 2 equiv of Zn(II). We used Co(II), which is an excellent 
surrogate for Zn(II) (32), to demonstrate that the Co(II) ions bind to the Zn1 and Zn2 sites in GLX2-1, including to 
the introduced His. After the R246H variant of GLX2-1 was made and characterized, the substrate binding amino 
acids of human GLX2 were introduced into the enzyme. The resulting enzymes were found to bind 0.5−1.2 equiv 
of Zn(II), regardless of whether excess Fe or Zn(II) was added to the enzymes (Table 2). Interestingly, the 
enzymes also bound ≥1.9 equiv of Fe if excess Fe was added to the proteins, suggesting that the R246H mutation 
exposes or creates additional Fe binding sites in GLX2-1. Fluorescence spectroscopy was used to evaluate 
whether the point mutations changed the tertiary structure of the GLX2-1 mutants. In all cases, the mutants 
exhibited similar or higher fluorescence emission than wild-type GLX2-1. This result indicates that the point 
mutations did not cause major folding alterations in the mutants but that the environment around one or more 
of Trp’s in the mutants has changed relative to wild-type GLX2-1. 
While replacement of Arg246 with a His had no effect on the ability of GLX2-1 to hydrolyze SLG, the metal-
loaded analogue of GLX2-1 R246H/N248Y exhibited significant SLG hydrolase activity (kcat of 22 ± 2 s−1; Table 2). 
In human GLX2, when Tyr175, which corresponds to Asn248 in GLX2-1 and Tyr240 in GLX2-5, was replaced by a 
phenylalanine, the resulting enzyme exhibited a 1.5-fold decrease in kcat and an 8-fold increase in Km(33). In the 
crystal structure of human GLX2, the hydroxyl group of Tyr175 is within hydrogen-bonding distance of the amide 
nitrogen of the glutathione glycine, and this interaction is thought to be a significant contribution to the binding 
of substrate (33). Our data demonstrate that this single point mutation transforms GLX2-1 into a catalytically 
active glyoxalase 2 enzyme. 
We attempted to prepare the single N248Y GLX2-1 variant to evaluate whether this mutation alone would 
afford glyoxalase 2 activity to GLX2-1; however, after purification, the N248Y variant contained only minor 
amounts of metal, and the metal content could not be increased to the levels of wild-type GLX2-1 by addition of 
excess metals followed by dialysis. The fluorescence emission spectrum of the enzyme suggested that it 
contained significant amounts of unfolded protein. We do not know the reason for this result; however, the 
computational model of GLX2-1 suggests that there could be steric problems with a tyrosine at position 248 
when an arginine is at position 246 (Figure 3). 
The role of several predicted SLG binding ligands was tested by introducing two additional mutations into GLX2-
1 R246H/N248Y to generate the GLX2-1 R246H/N248Y/Q325R/R328K variant. The metal-loaded form of this 
enzyme exhibited a 1.7-fold increase in kcat and a 1.3-fold decrease in Km, as compared to GLX2-1 R246H/N248Y 
(Table 2). This result is consistent with the fact that the rate-limiting step for GLX2 is substrate binding (34). 
Phe145, which corresponds to Ser219 in GLX2-1, was previously predicted to be involved in the binding of 
substrate to human GLX2; however, the introduction of a phenylalanine (S219F) to the GLX2-1 
R246H/N248Y/Q325R/R328K enzyme did not further increase kcat or decrease Km, suggesting that this residue 
does not play a major role in substrate binding. 
In order to further test if metal binding to His238 is involved in catalysis, we prepared the H238R mutant of 
GLX2-5. Like GLX2-1, the as-isolated H238R version of GLX2-5 binds significant amounts of metal, and a metal-
loaded form with >2 equiv of total metal could be generated (Table 2). EPR spectra suggest that the mutant 
contains a metal site similar to that of the wild-type enzyme. However, this metal-loaded analogue exhibited 
a kcat that is nearly 6-fold less than wild-type GLX2-5. This result suggests that, in addition to its role as a metal 
binding ligand, His238 may play a role in catalysis, possibly by orienting Tyr240 for proper substrate binding 
(Figure 3). However, some of the lost activity may be due to changes in the geometry/orientation of the metal 
center and/or the possibility that the H238R mutant is not as stable as the wild-type enzyme. The fluorescence 
spectrum of the GLX2-5 H238R enzyme showed a shoulder at 390 nm, suggesting that some of the protein in 
this sample was partially unfolded (Figure 7). In addition, the GLX2-5 H238R enzyme, unlike wild-type GLX2-5, 
was not stable to solvent exchange in NMR experiments (data not shown). These results suggest that, along with 
metal binding, His253 may have a role in catalysis and stability in GLX2 enzymes. 
 
Figure 7. Fluorescence emission spectra of wild-type GLX2-5 and the H238R mutant of GLX2-5. The 
concentration of samples was 10 μM, and the buffer was 10 mM MOPS, pH 7.2. An excitation wavelength of 295 
nm was used. 
 
One of the common, albeit surprising, aspects of the GLX2's is that many of the analogues bind more than two 
metal ions (see Table 2 as an example) (14, 27, 35). In an effort to identify any potential metal binding sites on 
GLX2-1, the homology model (Figure 3) was probed for any potential metal binding sites. A possible site, 
consisting of His179, Asp96, and Asp98, was identified (Figure 8 (left)). These same residues are conserved in 
GLX2-5 but not in human GLX2 (Figure 2). Interestingly, a remote metal binding site was also reported in human 
GLX2, consisting of His185, His235, and Glu251 (Figure 8 (right))(15). It is not clear if these remote metal binding 
sites affect structure/function of the GLX2's. 
 
Figure 8. (Left) Homology model of GLX2-1 showing a potential remote metal binding site consisting of Asp96, 
Asp98, and His179. (Right) Remote metal binding sites of human GLX2 on subunits A and B (15). The large dark 
sphere is a solvent molecule. 
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